ERBB2 and neoplasm: To restrict the PD-1 axis modulation to the tumor site and to boost T-cell function, we developed bicistronic vectors encoding a PD-1 checkpoint reversal receptor (CPR) and a HER2-CAR, with different permutations of signaling domains (CPR/CART).